RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)

Clinical Endocrinology

Volumn 74, Issue 2, 2011, Pages 241-247

  Romei, C ^a,b   Cosci, B ^a,b   Renzini, G ^a,b   Bottici, V ^a,b   Molinaro, E ^a,b   Agate, L ^a,b   Passannanti, P ^a,b   Viola, D ^a,b   Biagini, A ^a,b   Basolo, F ^c   Ugolini, C ^c   Materazzi, G ^c   Pinchera, A ^a,b   Vitti, P ^a,b   Elisei, R ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b WHO Collaborating Ctr for the Diagnosis and Treatment of Thyroid Cancer and Other Thyroid Diseases   (Italy)

^c Department of Surgery ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; EXON; FAMILIAL CANCER; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REARRANGED DURING TRANSFECTION GENETIC SCREENING; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASTIC SYNDROMES, HEREDITARY; POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; YOUNG ADULT;

EID: 78651342915     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03900.x     Document Type: Article

References (30)

1. Hazard, J.B., Hawk, W.A., &, Crile Jr, G., (1959) Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. Journal of Clinical Endocrinology and Metabolism 19, 152-161.
2. Melvin, K.E., &, Tashjian Jr, A.H., (1968) The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proceedings of the National Academy of Sciences of the United States of America 59, 1216-1222.
3. Keiser, H.R., Beaven, M.A., Doppman, J., et al. (1973) Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference. Annals of Internal Medicine 78, 561-579.
4. Cunliffe, W.J., Hudgson, P., Fulthorpe, J.J., et al. (1970) A calcitonin-secreting medullary thyroid carcinoma associated with mucosal neuromas, marfanoid features, myopathy and pigmentation. American Journal of Medicine 48, 120-126.
5. Farndon, J.R., Leight, G.S., Dilley, W.G., et al. (1986) Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. British Journal of Surgery 73, 278-281.
6. Brandi, M.L., Gagel, R.F., Angeli, A., et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86, 5658-5671.
7. Williams, E.D., &, Pollock, D.J., (1966) Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen's disease. The Journal of Pathology and Bacteriology 91, 71-80.
8. Carney, J.A., Go, V.L., Sizemore, G.W., et al. (1976) Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b. New England Journal of Medicine 295, 1287-1291.
9. Eng, C., Clayton, D., Schuffenecker, I., et al. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276, 1575-1579.
10. Donis-Keller, H., Dou, S., Chi, D., et al. (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 2, 851-856.
11. Mulligan, L.M., Kwok, J.B., Healey, C.S., et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460.
12. Eng, C., Smith, D.P., Mulligan, L.M., et al. (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Human Molecular Genetics 3, 237-241.
13. Elisei, R., Romei, C., Cosci, B., et al. (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Journal of Clinical Endocrinology and Metabolism 92, 4725-4729.
14. Kouvaraki, M.A., Shapiro, S.E., Perrier, N.D., et al. (2005) RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15, 531-544.
15. Kloos, R.T., Eng, C., Evans, D.B., et al. (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565-612.
16. Bugalho, M.J., Domingues, R., Santos, J.R., et al. (2007) Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141, 90-95.
17. Wiench, M., Wygoda, Z., Gubala, E., et al. (2001) Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. Journal of Clinical Oncology 19, 1374-1380.
18. Hecker, K.H., &, Roux, K.H., (1996) High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR. BioTechniques 20, 478-485.
19. Krstulovic, A.M., Dziedzic, S.W., Bertani-Dziedzic, L., et al. (1981) Plasma catecholamines in hypertension and pheochromocytoma determined using ion-pair reversed-phase chromatography with amperometric detection: investigation of the separation mechanism and clinical methodology. Journal of Chromatography 217, 523-537.
20. LiVolsi, V.A., (1997) C cell hyperplasia/neoplasia. Journal of Clinical Endocrinology and Metabolism 82, 39-41.
21. Pinchera, A., &, Elisei, R., (2006) Medullary thyroid cancer: diagnosis and management. In:, C.H.E.L. Mazzaferri, U.K. Mallick, P. Kendall-Taylor, eds. Practical Management of Thyroid Cancer. Springer-Verlag Limited, London, 255-279.
22. Niccoli-Sire, P., Murat, A., Rohmer, V., et al. (2001) Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. Journal of Clinical Endocrinology and Metabolism 86, 3746-3753.
23. Wiernik, P.H., Ashwin, M., Hu, X.P., et al. (2001) Anticipation in familial chronic lymphocytic leukaemia. British Journal Haematology 113, 407-414.
24. Shugart, Y.Y., Hemminki, K., Vaittinen, P., et al. (2001) Apparent anticipation and heterogeneous transmission patterns in familial Hodgkin's and non-Hodgkin's lymphoma: report from a study based on Swedish cancer database. Leukaemia & Lymphoma 42, 407-415.
25. Rodriguez-Bigas, M.A., Lee, P.H., O'Malley, L., et al. (1996) Establishment of a hereditary nonpolyposis colorectal cancer registry. Diseases of the Colon and Rectum 39, 649-653.
26. Dagan, E., &, Gershoni-Baruch, R., (2002) Anticipation in hereditary breast cancer. Clinical Genetics 62, 147-150.
27. Shifrin, A.L., Xenachis, C., Fay, A., et al. (2009) One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome-MEN 2C? Surgery 146, 998-1005.
28. Cranston, A.N., &, Ponder, B.A., (2003) Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. Cancer Research 63, 4777-4780.
29. Frank-Raue, K., Hoppner, W., Frilling, A., et al. (1996) Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. Journal of Clinical Endocrinology and Metabolism 81, 1780-1783.
30. Elisei, R., Cosci, B., Romei, C., et al. (2004) Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. Journal of Clinical Endocrinology and Metabolism 89, 5823-5827.